TY  - JOUR
AU  - Stokkel, Marcel P M
AU  - Gotthardt, Martin
AU  - Herrmann, Ken
AU  - Gnanasegaran, Gopinath
TI  - Theranostics in Perspective: White Paper.
JO  - Journal of nuclear medicine
VL  - 66
IS  - 7
SN  - 0097-9058
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2025-01016
SP  - 1007–1011
PY  - 2025
N1  - 66(7), pp. 1007–1011
AB  - Nuclear medicine has evolved from a diagnostic-oriented speciality toward theranostics. Radionuclide therapy has become a booming business with newer radiopharmaceuticals and indications. Although the specialty of nuclear medicine seems scintillating, several challenges might limit sustained and long-term success. Some of the challenges and issues requiring clarification include radiopharmaceutical cost and supply, cost-benefit analysis, reimbursement, training, workforce, collaboration with the radiopharmaceutical industry, national and international nuclear medicine, and applied specialities. This review discusses these challenges and possible solutions to avoid speed breakers in theranostics.
KW  - challenges (Other)
KW  - future (Other)
KW  - opportunities (Other)
KW  - radionuclide therapy (Other)
KW  - theranostics (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40374556
DO  - DOI:10.2967/jnumed.125.269776
UR  - https://inrepo02.dkfz.de/record/301474
ER  -